Chlamydia sequelae cost estimates used in current economic evaluations: does one-size-fit-all?

Ong, Koh Jun; Soldan, Kate; Jit, Mark; Dunbar, J Kevin; Woodhall, Sarah C

doi:10.1136/sextrans-2016-052597

Cited by 11 publications

(10 citation statements)

References 26 publications

(93 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…22 The upper-bound cost estimate for PID of $3677 is consistent with the cost study by Owusu-Edusei et al, 3 which applied a less conservative interpretation of the PID cost study by Yeh and colleagues. 22 The base case value of $2454 we calculated for this study (Table 2) incorporates data from a range of sources, [14][15][16][17][18][19][20][21][22] including data that have been published since the cost study by Owusu-Edusei et al 3 However, this new base case value we calculated was well within the lower-and upper-bound values reported by previous studies.…”

Section: Cost Of Chlamydia Gonorrhea and Trichomoniasissupporting

confidence: 55%

The Estimated Lifetime Medical Cost of Chlamydia, Gonorrhea, and Trichomoniasis in the United States, 2018

et al. 2021

View full text Add to dashboard Cite

show abstract

Section: Cost Of Chlamydia Gonorrhea and Trichomoniasissupporting

confidence: 55%

The Estimated Lifetime Medical Cost of Chlamydia, Gonorrhea, and Trichomoniasis in the United States, 2018

et al. 2021

View full text Add to dashboard Cite

show abstract

“…However, many cases of C. trachomatis infection are clinically asymptomatic [3] and remain undiagnosed, and as a consequence the actual prevalence is likely to be higher. A recent Health Technology Assessment report highlighted a 17% risk of pelvic inflammatory disease (PID) after C. trachomatis infection is untreated in women by the age of 44 [4], with costs to the NHS of treatment of C. trachomatis infections and subsequent complications estimated at between £37–£412 (approximately $57–$536) per case [5]. Current diagnostic protocols of C. trachomatis infection in women involve sampling genital tract samples and subsequent analysis by nucleic acid amplification test (NAAT).…”

Section: Introductionmentioning

confidence: 99%

Understanding the attitudes and acceptability of extra-genital Chlamydia testing in young women: evaluation of a feasibility study

et al. 2019

View full text Add to dashboard Cite

Background Chlamydia trachomatis (C. trachomatis) is the most common bacterial sexually transmitted infection in the UK. Recent studies suggest that in addition to the genital tract, C. trachomatis is found in the throat and rectum, suggesting the number of infections is under-reported. There is an urgent need to study the impact of extending diagnosis to include extra-genital samples; however, there is a lack of evidence on the acceptability of asking young women to provide these samples. Method A mixed methods single group feasibility study explored the acceptability of combined genital and extra-genital testing in young women aged 16–25 years consecutively attending a sexual health centre in Edinburgh, Scotland. Young women were asked to complete a self- administered anonymous questionnaire whether they would be willing to give self-taken throat and ano-rectal samples. Interviews with women ( n = 20) willing to self-sample were conducted before and after self-sampling, and these explored the underlying reasons behind their decision, and feelings about the tests. Results Of 500 women recruited to the study, 422 (84.4%) women provided sufficient data for analysis. From completed questionnaires, 86.3% of respondents reported willingness to self-sample from the throat. Willingness of ano-rectal self-sampling was lower (59.1%), particularly in women under 20 (< 20 years: 44.4%; ≥20 years, 68.2%). Willingness of ano-rectal self-sampling was higher in women who had more sexual partners in the last 6 months (0 partners, 48.3%, n = 14, 3 or more partners, 67.4%, n = 60) and in those who have previous experience of a positive test for a sexually transmitted infection (STI) (positive: 64.5%; negative: 57%). Interviewed women suggested that a lack of knowledge of STIs, embarrassment and lack of confidence in the ability to carry out the sampling were barriers towards acceptability. Conclusions In this study, self-sampling of throat samples is largely acceptable; however, the acceptability of taking an ano-rectal sample for C. trachomatis testing in young women was lower in younger women. The study suggests further research to investigate the acceptability of extra-genital testing as an addition to routine C. trachomatis testing, and whether this increases detection and prevents infective sequelae for women. Electronic supplementary material The online version of this article (10.1186/s12889-019-7313-0) contains supplementary material, which is available to authorized users.

show abstract

“…These sequelae account for substantial healthcare costs,3 and their prevention is an important reason for STI control policies 4…”

Section: Introductionmentioning

confidence: 99%

Rates of pelvic inflammatory disease and ectopic pregnancy in Australia, 2009–2014: ecological analysis of hospital data

et al. 2018

View full text Add to dashboard Cite

show abstract

Chlamydia sequelae cost estimates used in current economic evaluations: does one-size-fit-all?

Cited by 11 publications

References 26 publications

The Estimated Lifetime Medical Cost of Chlamydia, Gonorrhea, and Trichomoniasis in the United States, 2018

The Estimated Lifetime Medical Cost of Chlamydia, Gonorrhea, and Trichomoniasis in the United States, 2018

Understanding the attitudes and acceptability of extra-genital Chlamydia testing in young women: evaluation of a feasibility study

Rates of pelvic inflammatory disease and ectopic pregnancy in Australia, 2009–2014: ecological analysis of hospital data

Contact Info

Product

Resources

About